Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9587-9592

  Wang, Shi Yong ^a   Yang, Zhen Jun ^a   Zhang, Lu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy induced nausea and vomiting; Clinical trials; Malignant neoplasm; Olanzapine

Indexed keywords

EID: 84921516950     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9587     Document Type: Short Survey

References (37)

1. Brafford MV, Glode A (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol, 5, 24-9.
2. Copier J, Bodman-Smith M, Dalgleish A (2011). Current status and future applications of cellular therapies for cancer. Immunotherapy, 3, 507-16.
3. Chen W, Zheng R, Zhang S, et al (2014). Annual report on status of cancer in China, 2010. Chin J Cancer Res, 26, 48-58.
4. Daher M (2012). Cultural beliefs and values in cancer patients. Ann Oncol, 23, 66-9.
5. Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL (2014). The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. Drug Saf. [Epub ahead of print]
6. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.
7. Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
8. Hocking CM, Kichenadasse G. (2014). Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer, 22, 1143-51.
9. Ito F, Chang AE (2013). Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am, 22, 765-83.
10. Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.
11. Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.
12. Li F, Zhao C, Wang L (2014). Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer, 134, 1257-69.
13. McIntyre RS, Cha DS, Kim RD, et al (2013). A review of FDA-approved treatment options in bipolar depression. CNS Spectr, 18, 4-20.
14. Mizukami N, Yamauchi M, Koike K, et al (2013). Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage, [Epub ahead of print].
15. Moore MA, Sangrajrang S, Bray F (2014). Asian cancer registry forum 2014-regional cooperation for cancer registration: priorities and challenges. Asian Pac J Cancer Prev, 15, 1891-4.
16. Navari RM, Einhorn LH, Passik SD, et al (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer, 13, 529-34.
17. Navari RM, Einhorn LH, Loehrer PJ Sr, et al (2007). A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer, 15, 1285-91.
18. Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95.
19. Navari RM, Nagy CK, Gray SE (2013). The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21, 1655-63.
20. Navari RM (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol, 722, 180-6.
21. NCCN clinical Practice guidelines in oncology-Antiemesis Version I, 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
22. Pirl WF, Roth AJ (2000). Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncol, 9, 84-7.
23. Passik SD, Lundberg J, Kirsh KL, et al (2002). A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 23, 526-32.
24. Passik SD, Kirsh KL, Theobald DE, et al (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage, 25, 485-8.
25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Cancer. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8.
26. Passik SD, Navari RM, Jung SH, et al (2004). A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest, 22, 383-8.
27. Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43.
28. Sliwkowski MX, Mellman I (2013). Antibody therapeutics in cancer. Science, 341, 1192-8.
29. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
30. Tan L, Liu J, Liu X, et al (2009). Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res, 28, 131.
31. Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90.
32. Vardy J, Chiew KS, Galica J, et al (2006). Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94, 1011-5.
33. Vig S, Seibert L, Green MR (2014). Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol, 140, 77-82.
34. Welti J, Loges S, Dimmeler S, et al (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest, 123, 3190-200.
35. Wang SY, He Y, Zhang L, et al (2014). The effects of olanzapine, tropisetron and dexamethasone to preventing the nausea and vomiting induced by multi-day highly or moderately emetogenic chemotherapy in cancer patients. Chinese clinical oncology, CSCO, 544-5.
36. Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014). A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep, 4, 4813.
37. Yuan Lingyan, Jiao Xiaodong, Wang Zhan, et al (2013). Olanzapine combined granisetron and dexamethasone for the prevention of chemotherapy-induced emesis and nausea in cancer patients: A phase I trial. Chinese Clin Oncol, 18, 511-4.